Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial
The trial evaluated nivolumab in combination with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma, meeting its primary endpoint of progression-free survival at final analysis. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Renal Cell Cancer
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 15, 2020 Category: General Medicine Source Type: news
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2020-- AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 31, 2020 Category: Drugs & Pharmacology Source Type: news
Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
AKI promotes the development of papillary renal cell carcinoma from single progenitors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 26, 2020 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pathology, Journal, Source Type: news
Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
THURSDAY, March 26, 2020 -- Acute kidney injury (AKI) seems to promote the development of papillary renal cell carcinoma (pRCC) from single progenitors, according to a study published in the March 25 issue of Science Translational Medicine.
Anna... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2020 Category: Pharmaceuticals Source Type: news
Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCC
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Clinical trial exposes deadly kidney cancer's Achilles' heel
(UT Southwestern Medical Center) An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news
' Incredible' Results With Kidney Cancer Agent With Nobel Ties'Incredible' Results With Kidney Cancer Agent With Nobel Ties
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Novel targeted drug shows promise in advanced kidney cancer
(Dana-Farber Cancer Institute) Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news
Adding Ilixadencel Improved Outcomes in Metastatic RCC Adding Ilixadencel Improved Outcomes in Metastatic RCC
Combining intratumoral injections of ilixadencel with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Renal Function Change Found to be a Prognostic Factor for Cancer Specific Survival in RCC
The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
SIR highlights use of percutaneous ablation for RCC
Some patients with renal cell carcinoma (RCC) can be effectively treated nonsurgically...Read more on AuntMinnie.comRelated Reading:
SIR aims for more awareness of interventional radiology
SIR taps Findeiss as new president
SIR: Virtual reality beats fluoroscopy for catheter placement
SIR: 'OK, Google -- scrub up!'
SIR: Stroke treatment training program improves outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2020 Category: Radiology Source Type: news
Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery
The risk of recurrence in surgically treated renal-cell carcinoma (RCC) persists beyond five years after surgery, suggesting the need for continued surveillance, according to a new analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2019 Category: Consumer Health News Tags: Urology News Source Type: news
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
Progression - free survival longer in those receiving tivozanib as third - or fourth - line therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 23, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
MONDAY, Dec. 23, 2019 -- Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy, according to a study published online Dec. 3 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 23, 2019 Category: Pharmaceuticals Source Type: news
